NorthWest Health Prop Real Est Inv Trust (TSE:NWH.UN) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• NorthWest Health Prop Real Est Inv Trust shares surpassed their 200-day moving average, hitting a high of C$5.26 and last traded at C$5.17 with a trading volume of 507,147 shares.
• The company has a market capitalization of C$1.28 billion and a negative price-to-earnings ratio of -12.33, indicating financial distress.
• NorthWest Healthcare Properties REIT offers investors a diversified portfolio of healthcare real estate primarily in Australasia, Brazil, Germany, and Canada.

NorthWest Health Prop Real Est Inv Trust (TSE:NWH.UN - ) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$4.91 and traded as high as C$5.26. NorthWest Health Prop Real Est Inv Trust shares last traded at C$5.17, with a volume of 507,147 shares traded.

NorthWest Health Prop Real Est Inv Trust Stock Performance

The firm has a market capitalization of C$1.28 billion, a price-to-earnings ratio of -12.33, a P/E/G ratio of 0.74 and a beta of 1.53. The stock's fifty day moving average is C$4.94 and its two-hundred day moving average is C$4.91. The company has a quick ratio of 0.06, a current ratio of 0.25 and a debt-to-equity ratio of 129.42.

About NorthWest Health Prop Real Est Inv Trust

Northwest Healthcare Properties Real Estate Investment Trust provides investors with access to a portfolio of high-quality healthcare real estate. The company provides investors exposure to a well-diversified portfolio of healthcare real estate located in the greater areas of cities such as Australasia, Brazil, Germany, and Canada of which Australasia derives a majority of revenue to the company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.